ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1416

Higher Expression of Type 1 Interferon in Synovitis of Patient with Undifferentiated Arthritis before They Met Rheumatoid Arthritis Criteria Compared to Established Rheumatoid Arthritis.  a Retrospective Study with 14 Years of Follow-up

Andrea Cuervo1, Raquel Celis2, Julio Ramírez3, Alicia Usategui4, Regina Faré5, M. Victoria Hernández6, Virginia Ruiz-Esquide3, Jose Inciarte-Mundo7, Raimon Sanmarti8, Jose L. Pablos9 and Juan D. Cañete7, 1Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, 2Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, 3Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 4Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 5Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 6Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 7Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, 8Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, 9Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, Gene Expression, rheumatoid arthritis (RA) and synovitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Undifferentiated Arthritis (UA) is defined as an inflammatory oligo/poly arthritis that does not fulfil criteria for a definitive diagnosis.Delay in diagnosis and treatment leads to poor prognosis. The aim is to identify synovial biomarkers that may be useful to diagnose patients with early UA

Methods: Retrospective longitudinal study.Patients with UA followed in our Arthritis Unit,who underwent arthroscopy between 2000 and 2014.Synovial biopsy were stained by immunohistochemistry (IHQ) with the following antibodies:antiCD3 (T cells),antiCD20 (B cells),anti CD79 (preplasma cells), antiCD138(plasma cells),antiCD31(vessels),antiCD68(macrophages),antiCD15(neutrophils),antiCD117(mast cells),antihsp47(fibroblasts), and quantified by Digital Image Analysis (Olympus).The same antibodies were evaluated in RA and PsA control groups. A transcriptomic analysis was performed to study different pathways of inflammation; only the Type 1 Interferon pathway shown differences between RA and PsA, IHQ with MxA (one of the gene of Type 1 IFN signature) was performed.

Results: 54 UA and 78 controls were included.Table 1 shows the clinical, serological and demographic characteristics at time of synovial biopsy. Among patients with UA, 24 (44%) patients met criteria for RA and 30 (56%) for PsA during follow-up. Synovitis of patients with UA had higher macrophage(CD68+) density in total tissue(p=0.008) and sublining(SL)(p=0.012) than the control group.The UA that evolved to RA had a higher density of CD3 T lymphocytes than the control RA group(p=0.014).No differences were observed in cells of adaptive immunity(CD20 B lymphocytes,CD138 plasma cells),innate immunity(CD117 mast cells,CD15 neutrophils),vessels(CD31) between the 4 groups. The area(%) stained by anti-hsp47 (synovial fibroblasts) in SL was higher in the RA control group than in the PsA(p=0.003). The expression of MxA was increased in pre-RA Group compare to RA control (p=0.036) especially in patients with synovial lymphoidneogenesis

Conclusion: This is the first immunohistological study of synovitis in a significant group of patients with UA who developed AR or PsA during follow-up. Although there are some differences between the UA and control groups in the density of CD68+ macrophages and lymphocytes T CD3+, these do not appear to be useful for an early diagnosis of UA. On the other hand, unlike the results of some previous studies, we not found differences between the cellular infiltrate (adaptive immunity, innate immunity or vessels) in patients with RA and PsA. The Type 1 Interferon pathway could be a biomarker in patients with UA who develop RA, but a prospective study would be necessary to validate this results. The fact that some patients with UA were undergoing treatment prior to synovial biopsy and its retrospective character limit the results of this study.

Acknowledgements: Financed:“Fondo de Investigación Sanitaria” (PI14/00785. JDCañete) del Instituto de Salud Carlos III. (ISCIII).Co-financed by BECA FER-2015.Premis “Emili Letang”,Hospital Clínic.BECA MSD-Sociedad Catalana de Reumatología


Disclosure: A. Cuervo, None; R. Celis, None; J. Ramírez, Gebro, 2; A. Usategui, None; R. Faré, None; M. V. Hernández, None; V. Ruiz-Esquide, None; J. Inciarte-Mundo, None; R. Sanmarti, None; J. L. Pablos, None; J. D. Cañete, None.

To cite this abstract in AMA style:

Cuervo A, Celis R, Ramírez J, Usategui A, Faré R, Hernández MV, Ruiz-Esquide V, Inciarte-Mundo J, Sanmarti R, Pablos JL, Cañete JD. Higher Expression of Type 1 Interferon in Synovitis of Patient with Undifferentiated Arthritis before They Met Rheumatoid Arthritis Criteria Compared to Established Rheumatoid Arthritis.  a Retrospective Study with 14 Years of Follow-up [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/higher-expression-of-type-1-interferon-in-synovitis-of-patient-with-undifferentiated-arthritis-before-they-met-rheumatoid-arthritis-criteria-compared-to-established-rheumatoid-arthritis-a-retro/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/higher-expression-of-type-1-interferon-in-synovitis-of-patient-with-undifferentiated-arthritis-before-they-met-rheumatoid-arthritis-criteria-compared-to-established-rheumatoid-arthritis-a-retro/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology